Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Difinsa53 for Radiation Dermatitis in Breast Cancer
NCT02534129Phase 2Terminated
- Sponsor
- Protechsure Scientific
- Start
- Aug 2015
- Primary completion
- Mar 2016
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-blind, single-arm trial of difinsa53 in radiation dermatitis, sponsored by Protechsure Scientific. Primary endpoint: Radiation Dermatitis as Determined by Radiation Therapy Oncology Group (RTOG) Acute Radiation Morbidity Scoring Criteria at 8 weeks. Started Aug 2015; status: terminated.
02
Drugs
difinsa53
03
Conditions
radiation dermatitis
Beyond the preview
Go deeper on NCT02534129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02534129.